Noncoding RNAs in Pulmonary Arterial Hypertension: Current Knowledge and Translational Perspectives

Nadia Bernardi; Eva Bianconi; Andrea Vecchi; Pietro Ameri

doi:10.1016/j.hfc.2022.08.020

Noncoding RNAs in Pulmonary Arterial Hypertension: Current Knowledge and Translational Perspectives

Heart Fail Clin. 2023 Jan;19(1):137-152. doi: 10.1016/j.hfc.2022.08.020.

Authors

Nadia Bernardi¹, Eva Bianconi², Andrea Vecchi¹, Pietro Ameri³

Affiliations

¹ Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6, Genova 16132, Italy.
² Cardiovascular Disease Unit, Cardiac, Thoracic and Vascular Department, IRCCS Ospedale Policlinico San Martino - IRCCS Italian Cardiology Network, Largo Rosanna Benzi 10, Genova 16132, Italy.
³ Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6, Genova 16132, Italy; Cardiovascular Disease Unit, Cardiac, Thoracic and Vascular Department, IRCCS Ospedale Policlinico San Martino - IRCCS Italian Cardiology Network, Largo Rosanna Benzi 10, Genova 16132, Italy. Electronic address: pietroameri@unige.it.

PMID: 36435569
DOI: 10.1016/j.hfc.2022.08.020

Abstract

Several microRNAs and long noncoding RNAs contribute to pulmonary arterial hypertension (PAH) pathogenesis by impairing nitric oxide production, enhancing proliferation and migration and decreasing apoptosis of smooth muscle cells, and promoting endothelial-to-mesenchymal transition in pulmonary arteries. These noncoding RNAs (ncRNAs) could serve as both biomarkers and therapeutic targets for PAH. Nonetheless, the knowledge about their role in PAH is still incomplete. Furthermore, ncRNAs may vary across species and often act differently in different tissues and organs, and technical issues currently limit the implementation of ncRNA-based technologies. Additional studies are warranted to finally bring ncRNA into the clinical arena.

Keywords: Long noncoding RNA; Mechanisms; Pathogenesis; Pulmonary arterial hypertension; RNA; microRNA.

Publication types

Review

MeSH terms

Biomarkers
Humans
Hypertension, Pulmonary* / drug therapy
Hypertension, Pulmonary* / genetics
MicroRNAs* / genetics
MicroRNAs* / therapeutic use
Pulmonary Arterial Hypertension* / genetics
Pulmonary Artery

Substances

MicroRNAs
Biomarkers